Urocit^®-K (potassium citrate)

To Help Protect You From Another Kidney Stone Attack

If you've ever suffered from a kidney stone attack you will probably do anything in your power to prevent a recurrence. Luckily there's a specific preventative medical treatment that can greatly reduce the likelihood of your having another stone attack: UROCIT-K.

UROCIT-K is clinically proven to inhibit the formation of most stones in over 90% of patients.

Urocit-K is a patented formulation of potassium citrate. Urocit-K is available in slow-release wax-matrix tablets in 540 mg and 1080 mg strengths. Urocit-K is indicated for the treatment of calcium and uric acid kidney stones.

How Urocit-K Works

Urocit-K corrects the pH of the urine and elevates a naturally occurring urinary inhibitor. This helps control the formation of new stones.

Urocit-K's Delivery System

UROCIT-K utilizes a wax-matrix delivery system. This wax-matrix system delivers a slow, sustained release of medication which allows for convenient dosing, less gastrointestinal upset, and enhanced patient compliance.

What You Should Know About Urocit-K

UROCIT-K comes in a wax-matrix tablet. The active ingredient dissolves out of the matrix. However, because the matrix itself may not disintegrate completely, you may notice a remnant of the wax in the stool. This is normal. Do not be concerned. All the medication has dissolved and you have received the full therapeutic dose.

Contraindications:

UROCIT-K is contraindicated in those individuals with high levels of potassium in their blood serum due to such conditions as: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, and those taking a potassium-sparing agent (see Warnings).

Because of its ulcerogenic potential, UROCIT-K should not be taken by individuals with active peptic ulcers.

Warnings:

The use of UROCIT-K in patients with chronic renal failure, or any other condition which impairs potassium excretion, should be avoided.

Individuals taking a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride) should avoid taking UROCIT-K.

Adverse Reactions:

Some people, during treatment, may develop minor gastrointestinal irritation, such as: abdominal discomfort, vomiting, diarrhea, loose bowel movements or nausea. Such symptoms may be alleviated by taking UROCIT-K with meals or a snack.

If by any chance there is severe vomiting, abdominal pain, gastro-intestinal bleeding, or tarry stools, contact your physician immediately.

This material is intended to provide basic information. All medical advice, diagnosis and treatment should be obtained from your physician.